Silence Therapeutics plc (NASDAQ:SLN – Get Rating) was the target of a large drop in short interest in February. As of February 28th, there was short interest totalling 14,500 shares, a drop of 17.1% from the February 13th total of 17,500 shares. Based on an average daily volume of 45,400 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the stock are sold short.
Hedge Funds Weigh In On Silence Therapeutics
Several large investors have recently bought and sold shares of SLN. TCG Crossover Management LLC acquired a new position in shares of Silence Therapeutics in the third quarter worth about $21,122,000. BVF Inc. IL increased its position in Silence Therapeutics by 126.3% during the third quarter. BVF Inc. IL now owns 1,508,416 shares of the company's stock worth $14,888,000 after acquiring an additional 841,750 shares during the period. Point72 Asset Management L.P. increased its holdings in Silence Therapeutics by 120.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 550,875 shares of the company's stock valued at $5,528,000 after buying an additional 300,875 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Silence Therapeutics by 27.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company's stock valued at $18,350,000 after purchasing an additional 205,815 shares in the last quarter. Finally, M28 Capital Management LP acquired a new position in Silence Therapeutics during the 4th quarter worth about $2,225,000.
Get Silence Therapeutics alerts:Analysts Set New Price Targets
SLN has been the subject of a number of recent analyst reports. HC Wainwright cut their price target on shares of Silence Therapeutics from $95.00 to $80.00 and set a "buy" rating for the company in a report on Tuesday, December 6th. Morgan Stanley began coverage on shares of Silence Therapeutics in a report on Friday, December 9th. They issued an "equal weight" rating and a $18.00 target price for the company. Robert W. Baird lifted their target price on shares of Silence Therapeutics from $50.00 to $53.00 in a report on Thursday, January 26th. Finally, Chardan Capital decreased their price target on shares of Silence Therapeutics from $33.00 to $29.00 and set a "buy" rating for the company in a research report on Thursday, November 17th.
Silence Therapeutics Trading Up 0.3 %
NASDAQ SLN traded up $0.03 during trading hours on Tuesday, reaching $9.98. 25,896 shares of the company traded hands, compared to its average volume of 45,322. Silence Therapeutics has a 12 month low of $7.80 and a 12 month high of $21.32. The company has a 50 day moving average of $12.82 and a two-hundred day moving average of $12.66.
About Silence Therapeutics
(Get Rating)
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Recommended Stories
- Get a free copy of the StockNews.com research report on Silence Therapeutics (SLN)
- Monoclonal Antibodies? Avid Bioservices surges 32% on Blowout Q3
- GitLab Crashes On Guidance; Analysts Defend
- Healthcare Stocks With at Least 30 Years of Dividend Increases
- Coinbase Pops As SVB Crumbles To Dust
- Airlines Update Guidance, Shares Head For Different Destinations
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.